ABVX:EPA
Abivax SA
€77.00
arrow_upward
+0.46%(+0.35) 1D
Nov 19, 11:22:12 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€77.35
High
€77.40
Low
€76.40
Mkt. cap
6.74B
Avg. vol.
110.41K
Volume
9.20K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€77.35
High
€77.40
Low
€76.40
Mkt. cap
6.74B
Avg. vol.
110.41K
Volume
9.20K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
Business Insider
·
24 minutes ago
Why Morgan Stanley Says the S&P 500 Is Poised to Jump 18%
The Motley Fool
·
42 minutes ago
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Benzinga
·
35 minutes ago
Stock Market Today: Dow, S&P 500 Futures Rise as Wall Street Awaits Anthropic's Listing— PANW, NTES, SLS in Focus
FOREX.com
·
5 hours ago
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com